Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 14-May-2017

OncoGene

Abstract

A device for personalised cancer treatment: a move away from a 'one size fits all' approach to the treatment and care of breast cancer patients based on the proposed genomic device output results to provide a personalised treatment greatly improving the chances of survival of cancer patients.

Additional Questions

Who is your customer?

Cancer Clinics, DHBs, Academic and Pharma R&D laboratories

What problem does this idea/product solve or what market need does it serve?

The proposed device can offer a genomic diagnosis so that the oncologist can better understand the genetic base and can use this information to help select the most effective treatment, greatly improving chances of survival. Personalised medicine will help to save approximately $15billion that the healthcare provider or system currently spends on cancer drugs on each year and increase the survival rate of cancer patients.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Most of the time, the chemotherapy anti-cancer drugs damage normal cells than the cancer cells due to the random choice of generalised powerful anti-cancer drugs and treatment. The proposed new device will provide gene expression result within a short period of time by processing the patient's liquid biopsy samples. Based on comprehensive genomic and diagnostic characterization, different subtypes of patients within a given condition can be identified and treatment can be tailored to the underlying cause thereby saving the time, money and most importantly the life of a cancer patient.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

Our team has the potential to make our idea into a product as we have successfully formed a project team consisting of an Oncologist, a genomic scientist and a materials scientist with new-product development expertise. The current technology is based on histopathological result based on broad diagnosis, which takes 2 to 3 weeks to know the stage of a cancer patient. Whereas our cost-effective product is based on single cell analysis and provide real-time genetic information on the same day so that the oncologist can start the personalised treatment immediately based on the genetic information to be obtained from our device.